Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders

  • 378 clinical trials
  • 122 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic35Sjogren's syndrome31Endocrine ophthalmopathy27Neovascular age-related macular degeneration24Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema15Age-related macular degeneration12Dry eye12Asthma11Graves' disease11Retinitis pigmentosa11Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Mite allergy7Behcet's syndrome6Cataract6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

378 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

378 clinical trials

Mite allergy+1

Recruiting

Safety of a rush up‑dosing regimen of dust mite allergen extract versus conventional up‑dosing in adults with dust mite rhinitis/rhinoconjunctivitis with asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Phenol
  • Sponsor:HAL Allergy B.V.

Sjogren's syndrome

Recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Sjogren's syndrome

Recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Ocular myasthenia

Recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Uveal melanoma

Recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Giant cell arteritis

Recruiting

Study on the Effectiveness of Etanercept and Methotrexate for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Agencja Badań Medycznych

Conjunctivitis allergic

Recruiting

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Desloratadine
  • Sponsor:Allergy Therapeutics (UK) Limited

Sjogren's syndrome

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Endocrine ophthalmopathy

Recruiting

Safety and Tolerability of ETHY-001 Compared with Saline 0.9% in Adults with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Ethyreal Bio Inc.

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Conjunctivitis allergic+1

Recruiting

Efficacy of Tree SLIT-tablet and Betula pendula pollen extract in adolescents (12‑17) with allergic rhinitis/rhinoconjunctivitis caused by birch pollen

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Alk-Abello A/S

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept29 clinical trialsSodium Chloride17 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsDexamethasone Phosphate9 clinical trialsHistamine Dihydrochloride8 clinical trials
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.